Orlistat increases serum paraoxonase activity in obese patients.

摘要: Abstract Background and aim Previous studies have demonstrated that oxidative stress is increased in obese patients. The high-density lipoprotein (HDL) associated human paraoxonase 1 (PON1) can inhibit low-density oxidation has an antiatherogenic effect. Our objective was to assess the effects of orlistat therapy combined with diet on body mass index (BMI), waist circumference, lipid parameters, blood pressure, serum glucose level PON1 activity. Methods results A longitudinal, multicenter, randomized study without treatment performed. One hundred thirty nine otherwise healthy, subjects were divided two groups: 78 persons received (120 mg three times a day) while 61 kept only. Anthropometrical levels activity measured at baseline after 6 months treatment. BMI circumference reduced more pronouncedly group than control group. Patients receiving also had significantly greater improvements fasting pressure. orlistat-treated showed reduction total cholesterol triglyceride levels. In addition, these patients compared diet-only Conclusions 6-month beneficial effect profile improved antioxidant status by increasing However, because limited therapeutic effectiveness, hypercholesterolemia should receive additional lowering medications.